Apozeal Pharma, based in Levittown. P.A. 19057 is pleased to announce the launch of the first product Hydroxyzine HCL Solution, USP 10mg/5ml to U.S Market. Hydroxyzine HCL Solution, USP 10mg/5ml is US FDA approved and marketed in bottles of 1 Pint (473 mL). The drug product is indicated for the treatment of symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. It is useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritic. It is also used as sedative in certain circumstances. Apozeal is manufacturing the drug product at its Levittown PA facility in the US.

Apozeal Pharma will be launching 9 additional FDA approved products in its portfolio in the near future from its Levittown, PA facility. Apozeal also has plans to diversify to other pharmaceutical dosage forms, i.e. solid orals, injectables, biologics in the future.